Simply Wall St.
How the Narrative Surrounding Alector Has Changed After the Latozinemab Trial Failure
➖
AI Sentiment
Neutral
4/10
- Home
- ALEC
ALEC
Alector Inc.
as of 12-11-2025 3:46pm EST
$1.45
+$0.15
+11.54%
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
Chart Type:
Time Range:
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 133.2M | IPO Year: | 2019 |
| Target Price: | $3.50 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Hold | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.87 - $3.40 | Next Earning Date: | 11-06-2025 |
| Revenue: | $69,048,000 | Revenue Growth: | 12.26% |
| Revenue Growth (this year): | -83.01% | Revenue Growth (next year): | 160.66% |
AI-Powered ALEC Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 71.33%
71.33%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Alector Inc. (ALEC)
Rosenthal Arnon
Sell
Chief Executive Officer
ALEC Dec 3, 2025
Avg Cost/Share
$1.12
Shares
104,347
Total Value
$116,826.90
Owned After
2,420,040
SEC Form 4
Kenkare-Mitra Sara
Sell
President and Head of R&D
ALEC Dec 3, 2025
Avg Cost/Share
$1.12
Shares
41,687
Total Value
$46,672.77
Owned After
501,652
SEC Form 4
Wong-Sarad Grace
Sell
Principal Accounting Officer
ALEC Dec 3, 2025
Avg Cost/Share
$1.12
Shares
8,056
Total Value
$9,018.69
Owned After
127,735
SEC Form 4
Berkley Neil Lindsay
Sell
Chief Bus Ofcr & Interim CFO
ALEC Dec 3, 2025
Avg Cost/Share
$1.12
Shares
37,261
Total Value
$41,717.42
Owned After
374,309
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Rosenthal Arnon | ALEC | Chief Executive Officer | Dec 3, 2025 | Sell | $1.12 | 104,347 | $116,826.90 | 2,420,040 | |
| Kenkare-Mitra Sara | ALEC | President and Head of R&D | Dec 3, 2025 | Sell | $1.12 | 41,687 | $46,672.77 | 501,652 | |
| Wong-Sarad Grace | ALEC | Principal Accounting Officer | Dec 3, 2025 | Sell | $1.12 | 8,056 | $9,018.69 | 127,735 | |
| Berkley Neil Lindsay | ALEC | Chief Bus Ofcr & Interim CFO | Dec 3, 2025 | Sell | $1.12 | 37,261 | $41,717.42 | 374,309 |
Latest Alector Inc. News
ALEC Breaking Stock News: Dive into ALEC Ticker-Specific Updates for Smart Investing
Compare ALEC vs Leading Stocks
See how ALEC stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ALEC Alector Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.